Background and Aim: Circulating miRNAs exist in serum and plasma and they can be used
as a potential noninvasive molecular marker for colorectal cancer (CRC) diagnosis. The …

Recent breakthroughs in targeted therapy and immunotherapy have revolutionized the
treatment of lung cancer, the leading cause of cancer-related deaths in the United States and …

Conjunctival melanoma (CM) is an ocular malignant tumor arising from the bulbar and
palpebral conjunctiva and from the caruncle. The treatment of early-stage CM is wide local …

These findings demonstrate that lung cancers with compromised expression of enzymes
required for glutathione homeostasis, including reduced GSR gene expression, may be …

Cisplatin is effective as a single agent or in combination with other drugs for the treatment of
non‑small cell lung cancer (NSCLC). A concerning clinical challenge with cisplatin‑based …

Patients treated with immune checkpoint inhibitors (ICIs) often experience unique immune-related
adverse events (irAEs), and the previous studies demonstrated an association …

Objective Germline alterations in the breast cancer susceptibility genes type 1 and 2,
BRCA1 and BRCA2, predispose individuals to hereditary cancers, including breast, ovarian, …

Background: Selecting patients who potentially benefit from immune checkpoint inhibitors (ICIs)
is critical. Programmed death ligand-1 (PD-L1) protein immunohistochemical expression …

Colorectal cancer (CRC) is the third most common cancer and the fourth leading cause of
cancer‑associated mortalities worldwide. MicroRNAs (miRNAs/miRs) serve important roles in …

Thymic epithelial tumors (TETs) are a relatively rare type of thoracic tumor, accounting for less
than 1% of all tumors. The incidence of TETs is about 3.93/10000 in China, slightly higher …